🔗 Permalink

Inventor profile of:

Florian Holsboer

City:

Munchen

Country:

Germany

Published Applications:

Last publication date:

2019-12-05

Top Assignees for applications by Florian Holsboer

The entities that hold a legal rights for patent applications filed by inventor Holsboer Florian:

Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V. 2 Munich, Germany
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. 1 Munchen, Germany
Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E. V. 1 Munich, Germany
Max-Planck-Gesellschaft zur Förderung der Wisenschaften e. V. 1 Munchen, Germany
Max-Planck-Gesellschaft zur Forderung der Wissensc 1 Berlin, Germany
Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V. 1 , Germany
B.R.A.H.M.S GMBH 1 HENNIGSDORF, Germany
Max-Planck-Gesellschaft zur Förderung der Wisenschaften e.V. 1 Munich, Germany

Recent patent applications by Holsboer Florian

Florian Holsboer from Munchen, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2019-12-05

US20190365708A1

Human necessities

Vreceptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level

#2 | 2018-02-15

US20180042898A1

Human necessities

V1B RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF PATIENTS HAVING AN ELEVATED AVP LEVEL AND/OR AN ELEVATED COPEPTIN LEVEL

#3 | 2016-03-10

US20160067262A1

Human necessities

Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments

#4 | 2015-10-01

US20150278438A1

Physics

GENETIC PREDICTORS OF RESPONSE TO TREATMENT WITH CRHR1 ANTAGONISTS

#5 | 2015-06-04

US20150150846A1

Human necessities

V1B RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF PATIENTS HAVING AN ELEVATED AVP LEVEL AND/OR AN ELEVATED COPEPTIN LEVEL

#6 | 2015-04-02

US20150094310A1

Human necessities

CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY

#7 | 2013-09-26

US20130252822A1

Chemistry; metallurgy

Methods for Predicting an Antibody Response to Interferon Therapy in Multiple Sclerosis Patients

#8 | 2010-07-22

US20100184742A1

Human necessities

Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments

#9 | 2009-07-23

US20090186773A1

Chemistry; metallurgy

Methods for predicting the response of multiple sclerosis patients to interferon therapy and diagnosing multiple sclerosis

#10 | 2007-12-27

US20070298027A1

Chemistry; metallurgy

Novel Target for Antiderpressant Therapy

#11 | 2006-03-16

US20060057568A1

Chemistry; metallurgy

Method of identifying compounds that alter bag-1 mediated down-regulation of glucocorticoid-receptor transactivation

InventorID:

456901 ⎘